Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan
© Elamin et al; licensee BioMed Central Ltd. 2005
Received: 19 June 2005
Accepted: 14 September 2005
Published: 14 September 2005
Early diagnosis and effective treatment with an appropriate drug form the main components of the World Health Organization's strategy to reduce malaria related mortality. The few available drugs might be safeguarded if combined with artesunate. The addition of artesunate to a standard antimalarial treatment substantially reduces treatment failure, recrudescence and gametocyte carriage.
During late 2004, the efficacy of artesunate (4 mg/kg. day, on days 0–2) plus sulfadoxine-pyrimethamine (25 mg/kg, on day 0) for the treatment of uncomplicated Plasmodium falciparum malaria was investigated in four sentinel areas in Sudan, with different malaria transmission (Damazin, Kassala, Kosti, and Malakal).
Two hundreds and sixty-nine patients completed the 28-day follow-up. On day one, 60 (22.3%) patients were febrile and 15 (5.5%) patients were parasitaemic. On day three, all the patients were afebrile and aparasitaemic. While two patients (0.7%, Kassala) showed late Clinical and Parasitological Failures, the rest (99.3%) of the patients demonstrated Adequate Clinical and Parasitological Response. A gametocytaemia were detected during the follow-up in one patient (0.37%, Kassala). Adverse drug effects were detected in 32 (11.9%) patients
The study showed that AS plus SP is an effective, safe drug in the treatment of uncomplicated P. falciparum malaria in Sudan.
There are almost 515 (range 300–660) million episodes of clinical Plasmodium falciparum malaria infections . Drug-resistant malaria is spreading in Africa and countries with high levels of resistance have witnessed increased morbidity and mortality . Early diagnosis and effective treatment with an appropriate drug form the main components of the World Health Organization's strategy to reduce malaria-related mortality .
The few available drugs might be safeguarded if combined with artesunate. The addition of artesunate to standard antimalarial treatments substantially reduces treatment failure, recrudescence and gametocyte carriage, preventing the emergence and spread of drug resistance and interrupting the transmission of P. falciparum. Coupled with early detection and confirmed diagnosis, this strategy represents the only way forward in the chemotherapy of malaria [4–8].
Malaria causes between 7.5 to 10 million cases and 35,000 deaths every year in Sudan . Due to the spread of multidrug-resistant P. falciparum malaria in Sudan [10, 11], artesunate plus sulfadoxine-pyrimethamine is recommended as the first-line treatment for uncomplicated P. falciparum malaria. The study aimed to investigate the efficacy of AS plus SP, as there is little published data in Sudan [8, 12].
Patients and methods
The study was conducted in October and November, 2004 at four health centres in different regions of Sudan (Damazin, Kassala, Kosti, and Malakal) (Figure 1). Three of these areas were characterized by low malaria transmission and the fourth (Malakal) was characterized by stable transmission . Febrile (temperature ≥ 37.5°C) patients with uncomplicated P. falciparum malaria , who had no history of antimalarial drug use during the preceding two weeks, were recruited for the study. Pregnant women and patients with mixed infections were excluded.
Blood films were prepared, stained with Giemsa and 100x oil immersion fields were examined. The parasite density was counted against 200 leucocytes, assuming 6,000 leucocytes/μl. All the slides were double-checked blindly and only considered negative if no parasites were detected in 100 oil immersion fields. If gametocytes were seen, then the count was extended to 500 leucocytes.
Treatment and follow up
The patients were given the AS plus SP combination, with artesunate (4 mg/kg. day) given on days 0–2 and a single dose of SP (25 mg/kg) (Dafra Pharma, Beerse, Belgium) given on day 0. The tablets were crushed and dissolved in water for children who were not able to swallow them. Subjects were observed for vomiting for one hour; the full dose was repeated for those who vomited within 30 min and half of the dose was repeated if vomiting occurred between 30 and 60 minutes.
Follow-up and re-treatment
Patients were requested to come on days 1, 2, 3, 7, 14, 21 and 28 and at any time if they felt unwell. At each visit, body temperature was measured and blood films were prepared. During the follow-up the patients were asked if they suffered from side effects which can be expected from antimalarial treatment (nausea, vomiting, abdominal pain, dizziness and rash); these symptoms were considered to be drug related if they had not been reported at the patient's first presentation in the clinic.
Quinine was given for treatment failures. Early Treatment Failures (ETF) in case of significant parasitaemia at day 2 or 3 or parasites and fever at day 3. Late Clinical Failures (LCF) for cases with parasites and fever during follow-up after day 3 and Late Parasitological Failures (LPF) for parasite infections with/without fever during the follow-up. Cases which remained negative during follow-up were considered Adequate Clinical and Parasitological Responses (ACPR). These were modified WHO guidelines [14, 15].
Data were entered into a computer database and SPSS software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. The means (age, weight, temperature and parasite count) were calculated for all the patients and were compared between the patients in the different locations using one way analysis of the variance (ANOVA), when the data is normally distributed and by the Kruskal Wallis test if the data was not normally distributed. Percentages were calculated and compared for the patients in the four locations by an χ2 test. P < 0.05 was regarded significant.
The study received ethical clearance from the Sudanese National Malaria Administration.
The base line (day 0) characteristics of the 269 patients who completed the 28 days of follow-up after the treatment with artesunate plus sulfadoxine-pyrimethamine*.
Total (N = 269)
Damazin (N = 72)
Kassala (N = 50)
Kosti (N = 70)
Malakal (N = 77)
P < 0.05
P < 0.05
P > 0.05
Parasite count, rings/μ
P < 0.05
Children < 5 years
P < 0.05
P > 0.05
Trail profile, showing number of patients enrolled, treated and completing the 28 days of follow-up after the treatment with artesunate plus sulfadoxine-pyrimethamine*.
The recruited patients
Lost to follow-up
Patients completed the 28-days of follow-up
Accurate clinical and parasitological response
Late clinical and parasitological failure
The study investigated the efficacy of AS plus SP for the treatment of uncomplicated P. falciparum malaria at four sites in the Sudan. This is probably the largest study reporting AS plus SP efficacy in Sudan until now. Although, the baseline characteristics (age and parasite count) were significantly different between the four locations, the study showed that two (0.7%, Kassala) out of 269 patients were found to have Late Clinical and Parasitological Failures. Since the parasite genotyping (PCR) was not conducted, the possibility of re-infection/recrudescence is still there. Hundred percent efficacy of AS plus SP was recently reported from eastern Sudan  and 99% from southern Sudan . The high cure rate in this study is comparable to that reported from neighbouring African countries [5, 6]. However, the highest drug resistant P. falciparum strains were reported from eastern Sudan [11, 16]. The expected adverse effects (nausea, itching and dizziness) were reported in (11.9%) of the patients in this study. These results were in line with, observations of others, where the adverse effects were not significantly different, if compared with those of SP alone [5, 8].
The adverse effects (nausea, vomiting) might influence the adherence to AS plus SP, especially science this therapy is only available in the oral form, which is not the medication preferred by Sudanese patients . Furthermore, adherence may be influenced by the multiple doses of the combination, rather the previous single dose of SP, which was reported to be the most important single factor for the best adherence of SP among Sudanese patients .
A post- treatment gametocytaemia was detected in one patient in Kassala area. High (20%) levels of gametocytaemia had been reported in the eastern Sudan following SP, quinine and mefloquine treatment [18–20]. However, it has not been reported during the follow-up of patients in the eastern Sudan treated with artemether, artesunate plus mefloquine or AS plus SP [8, 19, 21]. The ability of artesunate to reduce the post-treatment gametocytaemia is important, as it may reduce transmission .
The study showed that, As plus SP is an effective, safe drug in the treatment of uncomplicated P. falciparum malaria in Sudan.
- Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI: The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005, 434: 214-217. 10.1038/nature03342.PubMed CentralView ArticlePubMedGoogle Scholar
- Zucker JR, Ruebush TK, Obonyo C, Otieno J, Campbell CC: The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya. Am J Trop Med Hyg. 2003, 68: 386-390.PubMedGoogle Scholar
- World Health Organization: A global strategy for malaria control. 1993, Geneva WHOGoogle Scholar
- Nosten F, Brasseur P: Combination therapy for malaria: the way forward?. Drugs. 2002, 62: 1315-1329.View ArticlePubMedGoogle Scholar
- Obonyo CO, Ochieng F, Taylor WR, Ochola SA, Mugitu K, Olliaro P, ter Kuile F, Oloo AJ: Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial. Trans R Soc Trop Med Hyg. 2003, 97: 585-591. 10.1016/S0035-9203(03)80038-X.View ArticlePubMedGoogle Scholar
- Priotto G, Kabakyenga J, Pinoges L, Ruiz A, Eriksson T, Coussement F, Ngambe T, Taylor WR, Perea W, Guthmann JP, Olliaro P, Legros D: Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trial. Trans R Soc Trop Med Hyg. 2003, 97: 325-330. 10.1016/S0035-9203(03)90161-1.View ArticlePubMedGoogle Scholar
- Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N: Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004, 363: 9-17. 10.1016/S0140-6736(03)15162-8.View ArticlePubMedGoogle Scholar
- Adam I, A/Elbasit I, Idris SM, Malik EM, Elbashir MI: A comparison of the efficacies of artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan. Ann Trop Med Parasitol. 2005, 449-455. 10.1179/136485905X36299.Google Scholar
- Malik EM, Khalafalla OM: Malaria in Sudan: past, present and the future. Gezira Journal of Health Sciences. 2004, 1 (suppl): 47-51.Google Scholar
- Adam I, Osman ME, ElGhazali G, Ahmed GI, Gustafson LL, Elbashir MI: Efficacies of chloroquine, sulphadoxine-pyrimethamine and quinine for the treatment of uncomplicated Plasmodium falciparum malaria in Eastern Sudan. Ann Trop Med Parasitol. 2004, 98: 661-666. 10.1179/000349804225021514.View ArticlePubMedGoogle Scholar
- Adam I, Elbashir MI: Resistance of P. falciparum to antimalarial drugs in Sudan: Review. Khartoum Med J. 2005,Google Scholar
- van den Broek I, Amsalu R, Balasegaram M, Hepple P, Alemu E, Hussein B, Al-Faith M, Montgomery J, Checchi F: Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan. Malar J. 2005, 4: 14-10.1186/1475-2875-4-14.PubMed CentralView ArticlePubMedGoogle Scholar
- Al Gadal AA: Malaria in the Sudan. Proceedings of the Conference on Malaria in Africa. Edited by: Buck AA. 1986, Washington, DC: American Institute of Biological Sciences, 156-159.Google Scholar
- World Health Organization: Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. Document WHO/MAL/96.1077. 1996, Geneva: WHOGoogle Scholar
- WHO: Assessment and Monitoring of Antimalarial Drug Efficacy for the treatment of uncomplicated Falciparum malaria. WHO/HTM/RBM/2003.50. 2003Google Scholar
- Salah MT, Mohammed MM, Himeidan YE, Malik EM, Elbashir MI, Adam I: A randomized comparison of sulphadoxine-pyrimethamine and combination of sulphadoxine-pyrimethamine with chloroquine in the treatment of uncomplicated falciparum malaria in Eastern Sudan. Saudi Med J. 2005, 26: 147-148.PubMedGoogle Scholar
- Abdel-Humeed AA: Malaria case management at the community level in Gezira Sudan. Afr J Med Sc. 2001, 30: 43-46.Google Scholar
- Adam I, Ibrahim MH, A/Elbasit I, Elbashir MI: Efficacy of sulphadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in a small sample of Sudanese children. East Mediterr Health J. 2004,Google Scholar
- Adam I, A/Elbasit I, Elbashir MI: Efficacies of mefloquine alone and artesunate followed by mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan. Ann Trop Med Parasitol. 2005, 99: 111-117. 10.1179/136485905X19801.View ArticlePubMedGoogle Scholar
- Adam I, Idris H, Mohamed-Ali AA, A/Elbasit IA, Elbashir MI: Quinine versus artemether in the treatment of severe falciparum malaria in Sudanese children. East Afr Med J. 2002, 79: 621-625.View ArticlePubMedGoogle Scholar
- Adam I, Salih I, Elbashir MI: Quinine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan. Trans R Soc Trop Med Hyg. 2005, 90: 736-738. 10.1016/j.trstmh.2005.05.005.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.